PacBio Grants Equity Incentive Award to New Employee
Jim Gibson to join PacBio as Chief Financial Officer
Pacific Biosciences of California, Inc. (NASDAQ: PACB) had its price target lowered by analysts at Scotiabank from $6.00 to $2.00. They now have a "sector outperform" rating on the stock.
Pacific Biosciences of California (PACB) Advances While Market Declines: Some Information for Investors [Yahoo! Finance]
Scientists Solve One of Genomics’ Biggest Challenges by Using HiFi Sequencing to Distinguish Highly Similar Paralogous Genes